Loading...
Docoh

Blueprint Medicines (BPMC)

News

From Benzinga Pro
Guardant Health and Blueprint Medicines Presenting Real-world Data Identifying EGFR C797X Mutation as Most Common Resistance Mechanism to Osimertinib Therapy at IASLC 2022 World Conference on Lung Cancer
8 Aug 22
News
Guardant Health Inc.
Where Blueprint Medicines Stands With Analysts
3 Aug 22
Analyst Ratings
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $143
3 Aug 22
News, Price Target, Analyst Ratings
Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $126 to $143.
SVB Leerink Maintains Market Perform on Blueprint Medicines, Raises Price Target to $65
3 Aug 22
News, Price Target, Analyst Ratings
SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and raises the price target from $56 to $65.
Raymond James Maintains Strong Buy on Blueprint Medicines, Lowers Price Target to $115
3 Aug 22
News, Price Target, Analyst Ratings
Raymond James analyst Dane Leone maintains Blueprint Medicines (NASDAQ:BPMC) with a Strong Buy and lowers the price target from $133 to $115.
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
2 Aug 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Blueprint Medicines: Q2 Earnings Insights
2 Aug 22
Earnings, News
Blueprint Medicines (NASDAQ:BPMC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Blueprint Medicines Q2 EPS $(2.68) Misses $(2.23) Estimate, Sales $36.55M Miss $37.24M Estimate
2 Aug 22
Earnings, News
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.68) per share which missed the analyst consensus estimate of $(2.23) by 20.18 percent. This is a 44.09 percent decrease over losses of $(1.86) per share
Earnings Scheduled For August 2, 2022
2 Aug 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
A Preview Of Blueprint Medicines's Earnings
1 Aug 22
Earnings
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-2.23.
3 Biotech Stock Picks From This Wedbush Analyst
27 Jul 22
Analyst Color, Biotech, Small Cap, Analyst Ratings, Trading Ideas, General
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
8 Jul 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Oppenheimer Initiates Coverage On Blueprint Medicines with Outperform Rating, Announces Price Target of $80
8 Jul 22
News, Price Target, Initiation, Analyst Ratings
Oppenheimer analyst Matthew Biegler initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Outperform rating and announces Price Target of $80.
Benzinga Pro's Top 5 Stocks To Watch For Friday, Jul. 1, 2022: GM, KSS, NIO, RIOT, BPMC
1 Jul 22
Pre-Market Outlook
Today's 5 Stock Ideas: General Motors (GM) - A Bank Of America analyst on Thursday noted both GM and Ford (F) will have overtaken Tesla (TSLA) in the electric vehicle market by 2025. Kohl's (KSS) -
Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis
1 Jul 22
News, FDA
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922
SVB Leerink Maintains Market Perform on Blueprint Medicines, Lowers Price Target to $56
1 Jul 22
News, Price Target, Analyst Ratings
SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
30 Jun 22
Analyst Color, Biotech, News, Health Care, Financing, Offerings, Analyst Ratings, General
Blueprint Medicines Announces Transformative $1.25B Strategic Financing Collaborations With Sixth Street And Royalty Pharma
30 Jun 22
News
Blueprint Medicines Corporation (NASDAQ:BPMC) today announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ:RPRX) for up to $1.25 billion, bringing significant non-dilutive, low-cost
What 7 Analyst Ratings Have To Say About Blueprint Medicines
27 Jun 22
Analyst Ratings
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
27 Jun 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades

Press releases

From Benzinga Pro
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
8 Aug 22
Press Releases
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4 Aug 22
Press Releases
CAMBRIDGE, Mass., Aug. 4, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
14 Jul 22
Press Releases
-- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ --
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
13 Jul 22
Press Releases
NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Blueprint Medicines Corporation - BPMC
11 Jul 22
Press Releases
New York, New York--(Newsfile Corp. - July 11, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7 Jul 22
Press Releases
CAMBRIDGE, Mass., July 7, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
5 Jul 22
Press Releases
NEW YORK, July 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
30 Jun 22
M&A, News, Press Releases
Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
30 Jun 22
Press Releases
Strengthens balance sheet with significant non-dilutive, low-cost capitalExpands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
23 Jun 22
News, Legal, Press Releases
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are advised to
Blueprint Medicines Appoints Habib Dable to its Board of Directors
23 Jun 22
Press Releases
CAMBRIDGE, Mass., June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
14 Jun 22
News, Legal, Press Releases
NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
9 Jun 22
News, Legal, Press Releases
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ:BPMC). Such investors are advised to
Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
9 Jun 22
Press Releases
-- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior standard therapies, to be presented at EHA 2022 Congress
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 Jun 22
Press Releases
CAMBRIDGE, Mass., June 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced